A Screening Study to Detect BRAF V600 Mutation-Positive Patients For Enrollment Into Clinical Research Studies of Zelboraf (Vemurafenib)
NCT ID: NCT01804140
Last Updated: 2016-11-02
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
662 participants
OBSERVATIONAL
2012-12-31
2013-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients with multiple myeloma must have received at least one line of prior systemic therapy for the treatment of multiple myeloma
Exclusion Criteria
* Uncontrolled concurrent malignancy
* Active or untreated CNS metastases
* History of known carcinomatous meningitis
* Prior treatment with a BRAF or MEK inhibitor (prior sorafenib is allowed)
* Uncontrolled, severe medical illness or condition as defined in protocol MO28072
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Genentech, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Genentech, Inc.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Sedona, Arizona, United States
Tucson, Arizona, United States
Burbank, California, United States
Rancho Cucamonga, California, United States
Denver, Colorado, United States
Ocala, Florida, United States
Woodbury, Minnesota, United States
Columbia, Missouri, United States
Las Vegas, Nevada, United States
Nashville, Tennessee, United States
Amarillo, Texas, United States
Austin, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Dallas, Texas, United States
Denton, Texas, United States
McAllen, Texas, United States
Tyler, Texas, United States
Spokane, Washington, United States
Yakima, Washington, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML28560
Identifier Type: -
Identifier Source: org_study_id